(Q39911248)

English

C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Fabrizio Manetti

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

object named as

Marco Radi

5

0 references

7

object named as

Maurizio Botta

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

author name string

Maria Alessandra Santucci

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Valentina Corradi

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Manuela Mancini

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Silvia Schenone

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

118-126

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

GROMACS 3.0: a package for molecular simulation and trajectory analysis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

21 January 2018

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual tyrosine kinase inhibitors in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Crystal structure of the T315I mutant of AbI kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted CML therapy: controlling drug resistance, seeking cure

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

GROMACS: fast, flexible, and free

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

GROMACS: A message-passing parallel molecular dynamics implementation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimization by Simulated Annealing

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of a genetic algorithm for flexible docking

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved protein-ligand docking using GOLD

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Part II: management of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to imatinib mesylate in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200800320

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CMDC.200800320

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39911248&oldid=1970751040"